Viking Therapeutics Shares Drop Amid Mixed Trial Results
TL;DR Summary
Viking Therapeutics' stock plummeted 40% after a Phase 2 trial showed its oral weight-loss drug, VK2735, was effective but had high discontinuation rates and side effects, raising concerns among investors about its tolerability and efficacy compared to competitors like Eli Lilly.
- Viking Therapeutics loses a third of its value after oral weight-loss drug trial MarketWatch
- Viking Therapeutics shares fall 40% on disappointing obesity pill trial data CNBC
- Viking Therapeutics (VKTX) Stock Fell More Than 30%. What Sent It Crashing. Barron's
- Viking's oral pill reduces up to 12.2% weight but shares slump on higher patient exits Reuters
- Viking Therapeutics Rises as Phase 3 Trials and Oral Formulation Progress Accelerate Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
88%
333 → 41 words
Want the full story? Read the original article
Read on MarketWatch